Canaccord Genuity reissued their buy rating on shares of Natera (NASDAQ:NTRA) in a report released on Wednesday morning, AnalystRatings.com reports. The firm currently has a $44.00 price target on the medical research company’s stock.
NTRA has been the topic of several other reports. ValuEngine lowered Natera from a buy rating to a hold rating in a research note on Wednesday, October 2nd. Piper Jaffray Companies set a $45.00 price target on Natera and gave the stock a buy rating in a research report on Friday, October 11th. BidaskClub upgraded Natera from a buy rating to a strong-buy rating in a research report on Tuesday, October 8th. Zacks Investment Research upgraded Natera from a sell rating to a hold rating in a research report on Friday, August 9th. Finally, Craig Hallum increased their price target on Natera from $29.00 to $37.00 and gave the stock a buy rating in a research report on Thursday, August 8th. Three equities research analysts have rated the stock with a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. Natera currently has an average rating of Buy and an average target price of $38.40.
Shares of NTRA stock traded up $0.52 during trading hours on Wednesday, hitting $38.51. The company had a trading volume of 842,566 shares, compared to its average volume of 807,450. Natera has a 12 month low of $11.08 and a 12 month high of $39.53. The firm has a market capitalization of $2.66 billion, a price-to-earnings ratio of -17.91 and a beta of 1.42. The firm’s fifty day moving average is $33.90 and its 200 day moving average is $26.77. The company has a debt-to-equity ratio of 1.10, a quick ratio of 2.42 and a current ratio of 2.54.
In related news, CEO Steven Leonard Chapman sold 98,996 shares of the stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $33.00, for a total transaction of $3,266,868.00. Following the sale, the chief executive officer now directly owns 20,061 shares in the company, valued at approximately $662,013. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, COO Robert Alan Schueren sold 12,545 shares of the stock in a transaction on Friday, September 20th. The shares were sold at an average price of $33.19, for a total value of $416,368.55. Following the completion of the transaction, the chief operating officer now owns 25,000 shares in the company, valued at $829,750. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 438,947 shares of company stock worth $13,888,596. 9.29% of the stock is owned by corporate insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in NTRA. Marshall Wace LLP bought a new position in Natera in the 1st quarter valued at $264,000. Focused Wealth Management Inc bought a new position in Natera in the 2nd quarter valued at $83,000. Moody Aldrich Partners LLC boosted its position in Natera by 16.9% in the 2nd quarter. Moody Aldrich Partners LLC now owns 50,491 shares of the medical research company’s stock valued at $1,393,000 after buying an additional 7,286 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. bought a new position in Natera in the 2nd quarter valued at $278,000. Finally, AGF Investments Inc. boosted its position in Natera by 240.0% in the 2nd quarter. AGF Investments Inc. now owns 170,000 shares of the medical research company’s stock valued at $4,689,000 after buying an additional 120,000 shares during the last quarter. Hedge funds and other institutional investors own 94.95% of the company’s stock.
Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.
See Also: Special Dividends
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.